Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15422486 | 0.98 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL7979150 | 0.93 | ASIC3 (0.50) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL7643355 | 0.92 | ASIC3 (0.49) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL17955854 | 0.88 | ASIC3 (0.51) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL3878859 | 0.86 | CES1 (0.44) | — | |
| SCHEMBL27946188 | 0.85 | HRH3 (0.47) | ADRA2AADRA2BADRA2CHRH3 | |
| SCHEMBL29758927 | 0.84 | HRH3 (0.42) | PNMTDRD2DRD3HRH3 | |
| SCHEMBL27928333 | 0.81 | ASIC3 (0.58) | DRD2DRD3HRH3 | |
| SCHEMBL19981613 | 0.80 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL27928328 | 0.79 | CD274 (0.47) | ADRA2AADRA2BADRA2CHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| CN-112469722-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-104619702-B | Fused cyclopentyl antagonists of CCR2 | 詹森药业有限公司 | 2017-09-15 | — | — | CN | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2569298-B1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-9150532-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-06 | — | — | US | disclosed |
| CN-104619702-A | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV | 2015-05-13 | — | — | CN | disclosed |
| US-20150080588-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2834234-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2015-02-11 | — | — | EP | disclosed |
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-0922035-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-02-07 | — | — | EP | disclosed |
| US-6143762-A | DRUGS AS DOPAMINE ANTAGONIST PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, PLC (GB) | 2000-11-07 | — | — | US | disclosed |
| US-6046210-A | ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-04 | — | — | US | disclosed |
| EP-0981516-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D?3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | EP | disclosed |
| CN-1224418-A | Tetrahydroisoquinoline derivs. as modulators of dopamine D3 receptors | SMITHKLINE BEECHAM PLC (GB) | 1999-07-28 | — | — | CN | disclosed |
| EP-0922035-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1999-06-16 | — | — | EP | disclosed |
| EP-0917530-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998049145-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998006699-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997043262-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | PNMT 2528/4885ADRA2A 33/4885ADRA2B 39/4885 |
| US-20150080588-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | PNMT 2757/4885ADRA2A 93/4885ADRA2B 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.